Equity research analysts tracking Organogenesis Holdings Inc. (NASDAQ: ORGO), a regenerative medicine and advanced wound care enterprise, project a cautious recovery path for the stock over the coming 12-month period. Consensus financial forecasts from Wall Street institutions indicate a wide target range, with average price expectations sitting significantly higher than its current trading price near $1.67 to $1.80 per share. While long-term projections point toward potential upside driven by expanding clinical product adoption in surgical and sports medicine markets, near-term consensus ratings lean toward hold or neutral as the company navigates volatile biotechnology sector trends and quarterly earnings fluctuations.